Department of Oncology and Haematology, Azienda Ospedaliero, Universitaria di Modena Ospedale Civile di Baggiovara, Modena, Italy.
Department of Health and Welfare, Emilia-Romagna Region, Bologna, Italy.
Cancer Med. 2020 Apr;9(7):2579-2589. doi: 10.1002/cam4.2824. Epub 2020 Feb 11.
Up to 10% of individuals with breast cancer (BC) belong to families with hereditary syndromes. The aim of this study was to develop an instrument to identify individuals/families at high-hereditary risk for BC and offer dedicated surveillance programs according to different risks.
The instrument consisted of a primary questionnaire collecting history of BC and ovarian cancer (OC). This questionnaire was applied to women enrolled in the Emilia-Romagna Breast Cancer Screening Program. General practitioners (GPs) and specialists could propose the same questionnaire too. Women with a score of ≥ 2, were invited to complete an oncogenetic counseling. According to the Tyrer-Cuzick evaluation, women considered at high risk were invited to involve the most representative alive individual of the family affected with BC/OC for BRCA1/2 genetic testing.
Since January 2012 and December 2016, 660 040 women were evaluated by the regional screening program, of which 22 289 (3.5%) were invited to the Spoke evaluation, but only 5615 accepted (25.2%). Totally, also considering women sent by GPs and specialists, 11 667 were assessed and 5554 were sent to the Hub evaluation. Finally, 2342 (42.8%) women fulfilled the criteria for genetic testing, and 544 (23.2%) resulted BRCA1/2 mutation carriers.
To our knowledge, this is the first regional population-based multistep model that is aimed to identify individuals with BRCA1/2 mutations and to offer an intensive surveillance program for hereditary-high risk women. This tool is feasible and effective, even if more efforts must be performed to increase the acceptance of multiple assessments by the study population.
多达 10%的乳腺癌(BC)患者属于遗传性综合征家族。本研究旨在开发一种工具,以识别 BC 高遗传风险个体/家族,并根据不同风险提供专门的监测计划。
该工具由一个主要问卷组成,收集 BC 和卵巢癌(OC)病史。该问卷应用于参加艾米利亚-罗马涅乳腺癌筛查计划的女性。全科医生(GP)和专家也可以提出同样的问卷。评分≥2 的女性被邀请完成肿瘤遗传学咨询。根据 Tyrer-Cuzick 评估,被认为高风险的女性被邀请邀请受 BC/OC 影响的家族中最具代表性的在世个体进行 BRCA1/2 基因检测。
自 2012 年 1 月至 2016 年 12 月,该地区筛查计划共评估了 660,040 名女性,其中 22,289 名(3.5%)被邀请参加 Spoke 评估,但只有 5615 名(25.2%)接受了邀请。总共,还考虑了由 GP 和专家转介的女性,有 11,667 人接受了评估,其中 5,554 人被转介到 Hub 评估。最终,2,342 名(42.8%)女性符合基因检测标准,544 名(23.2%)为 BRCA1/2 突变携带者。
据我们所知,这是第一个针对个体识别 BRCA1/2 突变并为遗传性高风险女性提供强化监测计划的基于人群的多步骤区域模型。该工具是可行和有效的,即使需要付出更多努力来提高研究人群对多次评估的接受度。